Magazine article Drug Topics

New Guide Adds Options for Kidney Cancer

Magazine article Drug Topics

New Guide Adds Options for Kidney Cancer

Article excerpt

Recent drug approvals have given pharmacists and physicians new options for treating kidney cancer. And now there's an updated treatment guideline from the National Comprehensive Cancer Network (NCCN) to help clinicians utilize the new drugs in the most appropriate manner. The guide is based on current scientific evidence and was released in August as an update to NCCN's Clinical Practice Guidelines in Oncology.

"Temsirolimus [Torisei, Wyeth] is now recommended as a first-line treatment [category 1] option in renal cell cancer patients with predominant clear cell histology who also have poor Memorial Sloan-Kettering Cancer Center [MSKCC] prognostic risk factors," said Cheryl A. Grandinetti, Pharm.D., senior clinical research pharmacist at the National Cancer Institutes Cancer Therapy Evaluation Program. NCCN has included temsirolimus as first-line therapy for patients with non-clear cell histology, she added.

In the new document, the term second-line therapy has been changed to subsequent therapy and the category designations for sunitinib (Sutent, Pfizer) and sorafenib (Nexavar, Bayer) were clarified. Although clinical trials are preferred for subsequent therapy for metastatic disease, both drugs are considered category 1 when used after cytokine therapy and are considered category 2B when used after a prior kinase inhibitor. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.